Team finds microRNA that could be used to suppress prostate cancer progression

May 16, 2014

About one in seven men will develop prostate cancer over the course of a lifetime, and about one in 36 men will die from it.

This is why findings by Cincinnati Cancer Center researchers, showing that a tumor suppressive microRNA, when activated by an anti-estrogen drug, could contribute to development of future targeted therapies, are important.

These findings are published in the May 16, 2014 edition of the journal PLOS ONE.

"MicroRNAs, or miRNAs, are short RNA molecules that play a prominent role in regulating . One miRNA can target multiple genes, but their expression is often hijacked by and disrupts multiple cancer-causing or tumor-suppressing pathways," says Shuk-Mei Ho, PhD, director of the CCC and Jacob G. Schmidlapp Chair of Environmental Health and professor at the University of Cincinnati (UC) College of Medicine.

She along with Ricky Y.K. Leung, PhD, member of the CCC, assistant research professor in the department of environmental health and member of the UC Cancer Institute, and their team identified a new miRNA, known as hsa-miR-765, which is specifically activated by a Food and Drug Administration (FDA)-approved anti-estrogen drug (fulvestrant).

"This miRNA suppresses expression of HMGA1, a gene that was shown in previous studies to be associated with and recurrence," says Leung. "These findings do not only contribute to new insights on the effects of anti-estrogen but also the potential of using miRNA for monitoring drug efficacy and for future RNA-based therapy developments.

"This study also highlights the potential use of this anti-estrogen or miRNA in patients with recurrent prostate cancer, for whom there is no treatment, and raises the possibility of using anti-estrogen or miRNA treatments in preventing or slowing progression for primary prostate cancer."

Using cultured prostate cancer specimens from patients who were given a single 250 mg dose of fulvestrant, researchers found that hsa-miR-765 acted as a tumor suppressor when its expression was increased by the use of fulvestrant.

"Both the anti-estrogen and the hsa-miR-765 mimic suppressed HMGA1 protein expression," Ho says. "Levels of hsa-miR-765 were increased, and HMGA1 was almost completely lost in prostate cancer specimens from patients treated with a single dose of fulvestrant 28 days before removal of their prostate glands.

"These findings reveal a unique fulvestrant signaling process involving the increased regulation of hsa-miR-765 that suppresses the HMGA1 protein as part of the mechanism underlying the tumor suppressor action in . This could lead to newer treatment options with less toxicity for these patients."

Related Stories

Researchers identify key protein's role in cancer development

August 30, 2013

Researchers at the University of Cincinnati (UC) have identified a key protein as the first dual-function co-regulator of an estrogen receptor that plays a crucial role in cancer development, opening the way to improved therapeutic ...

BPA linked to prostate cancer, study shows

March 3, 2014

Findings by Cincinnati Cancer Center researchers show that levels of bisphenol A (BPA) in men's urine could be a marker of prostate cancer and that low levels of BPA exposure can cause cellular changes in both non-malignant ...

A gene family that suppresses prostate cancer

March 13, 2014

Cornell University researchers report they have discovered direct genetic evidence that a family of genes, called MicroRNA-34 (miR-34), are bona fide tumor suppressors.

Recommended for you

Strange circular DNA may offer new way to detect cancers

July 30, 2015

Strange rings of DNA that exist outside chromosomes are distinct to the cell types that mistakenly produced them, researchers have discovered. The finding raises the tantalizing possibility that the rings could be used as ...

New treatment options for a fatal leukemia

July 27, 2015

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

dedereu
not rated yet May 17, 2014
Another simple method decreases strongly the progression rate, as explained in the China Study by T Colin Campbell :
eat quite less animal proteins like milk, cheese and meat !!
And make a lot of exercice each day, running in climbing stairs !!

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.